Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PTAFR | P25105 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846343 | 0.87 | HIF1A (0.56) | HIF1AMAPTRAB9ANPC1LMNA | |
| SCHEMBL1394203 | 0.83 | RAB9A (0.74) | HIF1AMAPTRAB9ANPC1LMNA | |
| SCHEMBL10133033 | 0.79 | TUBB4A (0.53) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL483578 | 0.79 | RAB9A (0.74) | MAPTRAB9ANPC1LMNAPOLB | |
| SCHEMBL6224886 | 0.79 | MCHR1 (0.54) | HIF1AMAPTTP53RAB9ANPC1 | |
| SCHEMBL28606401 | 0.79 | HIF1A (0.72) | HIF1AMAPTRAB9ANPC1LMNA | |
| SCHEMBL10133038 | 0.79 | MEN1 (0.72) | HIF1ARAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL13073425 | 0.75 | HDAC2 (0.76) | HIF1AMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2409836 | 0.75 | HIF1A (0.44) | HIF1AMAPTRAB9ANPC1POLB | |
| SCHEMBL28344799 | 0.74 | HIF1A (1.00) | HIF1AMAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| WO-2009009041-A2 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | MAP3K6, MAP3K4, MAP3K3 | HIF1A 1753/4885MAPT 2664/4885TP53 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.